REPRIEVE Study: AlbanyMed

June 5, 2024

Target Audience

All pharmacists

Learning Objectives

After the Event You will be able to:

  • Describe elevated cardiovascular risk in persons with HIV
  • Define main results of the REPRIEVE trial
  • Identify implications of the REPRIEVE trial for primary prevention of cardiovascular disease in persons with HIV
Course summary
Available credit: 
  • 1.00 ACPE
    The Arnold & Marie Schwartz College of Pharmacy and Health Sciences is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Course opens: 
06/03/2024
Course expires: 
11/21/2025
Event starts: 
06/05/2024 - 6:00pm EDT
Event ends: 
06/05/2024 - 7:00pm EDT
Cost:
$0.00
Add to calendar: 
Rating: 
0

Dr. Fichtenbaum's expertise is in clinical research in infectious diseases, with a focus on HIV infection and the intersection of HIV and cardiovascular disease. Dr. Fichtenbaum is Principal Investigator of the Infectious Diseases Research Unit at UC.  He is board certified by the American Board of Internal Medicine and Infectious Diseases. Dr. Fichtenbaum has been elected as a Fellow to the American College of Physicians, HIV Medical Association, and Infectious Diseases Society of America. His published works include approximately more than 175 articles, 135 abstracts and various reviews, book chapters and letters.

ACPE UAN #

0042-9999-24-046-L02-P

 

Available Credit

  • 1.00 ACPE
    The Arnold & Marie Schwartz College of Pharmacy and Health Sciences is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

You will need a device that allows you to hear and see the presentation. Some phones may have limited functionality.